153773-82-1
中文名称
尔他培南钠
英文名称
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-ca rboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethy l)-4-methyl-7-oxo-, monosodium salt, (4R,5S,6S)-
CAS
153773-82-1
分子式
C22H26N3NaO7S
分子量
499.51
MOL 文件
153773-82-1.mol
更新日期
2025/05/22 10:56:47
153773-82-1 结构式
基本信息
中文别名
尔他培南钠厄他培南粗品
厄他培南钠盐
(4R,5S,6S)-3-[[(3S,5S)-5-[[(3-羧基苯基)氨基甲酰基]吡咯烷-3-基]硫-6-(1-羟基乙基)-4-甲基-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-甲酸钠盐
(4R,5R,6S)-3-[(3S,5S)-5-[(3-羧基苯基)氨基甲酰基]吡咯烷-3-基]硫-6-(1-羟乙基)-4-甲基-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-甲酸钠盐/厄他培南钠盐/尔他培南钠盐/呃他培南钠盐
英文别名
Invanz3-(((3S
L 749345
EtapeneM
Etapenem sodium
ErtapeneM Crude
ErtapeneM MonosodiuM
Ertapenem Impurity 16
Ertapenem sodium, >=97%
He Seoul sodium imipenem
所属类别
原料药：β-内酰胺酶抑制剂物理化学性质
熔点>174oC (dec.)
储存条件-70°C
溶解度可溶于DMSO（轻微）、甲醇（轻微）、水（轻微、超声处理）
形态粉末
颜色白色至米色
水溶解性Fully miscible in water. Soluble in DMSO.
稳定性吸湿性、温度敏感
厄他培南钠价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-13625 | 厄他培南钠 Ertapenem sodium | 153773-82-1 | 1 mg | 187元 |
| 2025/05/22 | HY-13625 | 厄他培南钠 Ertapenem sodium | 153773-82-1 | 5 mg | 375元 |
| 2025/05/22 | HY-13625 | 厄他培南钠 Ertapenem sodium | 153773-82-1 | 10 mg | 600元 |
常见问题列表
生物活性
Ertapenem sodium (L-749345; MK-826) 属于长效的碳青霉烯，是一种 β-内酰胺抗生素，具有广泛的抗菌谱。Ertapenem sodium 对革兰氏阳性菌和革兰氏阴性菌均有活性，包括肠杆菌科、肺炎链球菌和大多数种类的厌氧菌。体外研究
Ertapenem sodium inhibits
Streptococcus pneumoniae
with MIC
50
s values < 1mg/L.
Ertapenem sodium exhibits a bactericidal mode of action as shown by time-killing curves and exhibits a short postantibiotic effect (PAE) of 1.4-2.6 h against the Gram-positive strains but no PAE against Gram-negative strains.
体内研究
Ertapenem sodium (50 mg/kg; s.c.; q6h; for 24 hours) shows substantial bactericidal activity against
S. pneumoniae
in the murine thigh infection model.
Ertapenem sodium exhibits an AUC
0-24
of 586 mg•h/L, C
max
of 140 mg/L following subcutaneous injection (mice 50 mg/kg).
| Animal Model: | Specific-pathogen-free female ICR mice (~25 g), thigh infection model |
| Dosage: | 50 mg/kg |
| Administration: | Subcutaneous injection, q6h, for 24 hours |
| Result: | Showed substantial bactericidal activities. |
| Animal Model: | Specific-pathogen-free female ICR mice (~25 g), thigh infection model |
| Dosage: | 20 mg/kg, 50 mg/kg, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Subcutaneous injection |
| Result: | AUC 0-24 (586 mg•h/L), C max (140 mg/L) at 50 mg/kg q6h dosing regimen. |